在患有原发性丸扩散型大B细胞淋巴瘤的患者中开发和验证生存名录
Yongjin Zhi1, Shuojing Bao2, Jingcheng Mao1
1Department of Hematology, Taizhou People's Hospital affiliated to Nanjing Medical University, Taizhou, Jiangsu Province, China.
The Journal of international medical research
|September 7, 2023
概括
一个新的诺米图预测了原发性丸扩散型大B细胞淋巴瘤 (PT-DLBCL) 的存活率. 这个工具可以帮助医生个性化治疗策略,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 生物统计学 生物统计学
背景情况:
- 初级丸扩散大B细胞淋巴瘤 (PT-DLBCL) 是一种罕见的非霍奇金淋巴瘤.
- 对于PT-DLBCL有效的治疗计划,需要准确的预后工具.
研究的目的:
- 在PT-DLBCL患者中开发和验证用于预测整体存活率 (OS) 和癌症特异性存活率 (CSS) 的名录.
- 为了确定PT-DLBCL的独立预后因素.
主要方法:
- 利用监测,流行病学和最终结果 (SEER) 数据库对PT-DLBCL病例 (2000-2019年) 的数据库.
- 开发了一个基于通过单变量和多变量考克斯回归识别的独立预后因素的诺莫图.
- 使用培训和验证队列验证名录,评估区分和校准与一致性指数和ROC分析.
主要成果:
- 包括1099个PT-DLBCL病例,随机分为培训 (n=771) 和验证 (n=328) 队列.
- 确定了五个关键的预后指标:年龄,治疗方式,诊断年份,安纳伯阶段和横向性.
- 诺米图表表现出卓越的预测性能,在两个队列中,OS和CSS的一致性指数高.
结论:
- 开发的诺米图谱为预测PT-DLBCL的存活率提供了可靠的工具.
- 这种预后模型可以帮助临床医生为PT-DLBCL患者量身定制个性化治疗策略.
相关概念视频
01:21Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
01:20Comparing the Survival Analysis of Two or More Groups
220
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
220